Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514867 | 0.94 | L3MBTL1 (0.47) | KMT2AMEN1POLBL3MBTL1ALDH1A1 | |
| SCHEMBL2976035 | 0.79 | POLB (0.56) | KMT2AMEN1POLBL3MBTL1ALDH1A1 | |
| SCHEMBL2976094 | 0.78 | POLB (0.55) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL3562876 | 0.77 | POLB (0.56) | KMT2AMEN1POLBSMN1; SMN2CCNC | |
| SCHEMBL3514397 | 0.75 | POLB (0.44) | KMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL3515182 | 0.75 | CYP2D6 (0.55) | KMT2AMEN1POLBL3MBTL1ALDH1A1 | |
| SCHEMBL9934430 | 0.74 | MEN1 (0.51) | KMT2AMEN1POLBCTSSBRD4 | |
| SCHEMBL1531267 | 0.74 | POLB (0.48) | KMT2AMEN1POLBKITALDH1A1 | |
| SCHEMBL1912062 | 0.73 | POLB (0.56) | KMT2AMEN1POLBL3MBTL1ALDH1A1 | |
| SCHEMBL7451023 | 0.73 | POLB (0.56) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | KMT2A 1287/4885MEN1 3912/4885POLB 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.